Replies to post #369197 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

No reason to worry: My fear is that healthcare insurers will be initially reluctant to pay for Blarcamesine.

Blarcamesine will be far cheaper than adulhelm and Medicare will approve it if the FDA does. No way insurers can hold out if Medicare approves.

[RedShoulder]

My fear is that healthcare insurers will be initially reluctant to pay for Blarcamesine.

Actually A2-73 Blarcamesine will save insurance companies and tax payers a very significant amount money if it stops or significantly slows the progression of Alzheimer disease, and improves the patient cognition on a significant amount of the A.D. patient population. The current SOC bar is very low.

In the latter stages nursing home is usually required and that adds a significant financial burden to the family. (I'm speaking from personal experience too as my grandmother had A.D. was in a nursing home for 2 years before passing away and I was the primary care taker).

Alzheimer disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. The estimated total healthcare costs for the treatment of Alzheimer disease in 2020 is estimated at $305 billion, with the cost expected to increase to more than $1 trillion as the population ages. Most of the direct costs of care for Alzheimer disease are attributed to skilled nursing care, home healthcare, and hospice care. Indirect costs of care, including quality of life and informal caregiving, are likely underestimated and are associated with significant negative societal and personal burden.

https://www.ajmc.com/view/economic-burden-of-alzheimer-disease-and-managed-care-considerations

[raja48185]

The only opinions that matter are the FDA experts

That is what I am nervous about.